Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Table 2 Summary of published clinical trials involving modulators of novel forms of RCDs

Trial number	Condition and disease	Drug/Treatment	Number of included patients	Function	Phase
NCT04229992	Colorectal cancer	Magnesium glycinate, Placebo	240 participants	Necroptosis induction	NA
NCT04739618	Metastatic cancer	Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF	32 participants	Necroptosis induction	Phase 2
NCT02965703	Colorectal adenoma	Aspirin	81 participants	Necroptosis induction	Phase 2
NCT03803774	Locally recurrent head and neck squamous cell carcinoma, nasopharyngeal squamous cell carcinoma, sinonasal squamous cell carcinoma	Birinapant, Intensity-Modulated Radiation Therapy	34 participants	Necroptosis induction	Phase 1
NCT03681951	Pancreatic cancer	GSK3145095, GSK3145095 + Pembrolizumab	8 participants	Necroptosis inhibitor	Phase 2
NCT05493800	Oral Mucositis, lymphoma, multiple myeloma hematologic cancer	MIT-001, normal saline	75 participants	Ferroptosis inhibitor	Phase 2

ISSN: 1756-8722